---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-203889"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2024-08-21T23:59:59+00:00"
generated_at: "2026-05-31T08:13:12.150295+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Aadi halts PRECISION1 trial for TSC1/TSC2 cancers; cuts R&D staff 80%, extends cash runway into 2H 2026

## Summary
- PRECISION1 trial halted; IDMC found it unlikely to meet efficacy threshold for accelerated approval; 25 benefiting patients eligible for expanded access.
- FYARRO Q2 2024 sales of $6.2M; company will focus on FYARRO commercial business for PEComa.
- Workforce reductions: 22 employees (32% total) and 80% of R&D staff; non-recurring charges estimated $2.2-2.5M in Q3 2024.
- Cash runway extended into at least 2H 2026; company hired advisory firm for comprehensive strategic review to maximize shareholder value.

## SEC filing metadata
- accession: 0001193125-24-203889
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2024-08-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312524203889/0001193125-24-203889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312524203889/d859038d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-203889
- JSON: https://secwatch.observer/filing/0001193125-24-203889.json
- Plain text: https://secwatch.observer/filing/0001193125-24-203889.txt

## Key facts
- Restructurings & Charges
  Whitehawk Therapeutics, Inc. announced a restructuring with charges of approximately $2.2 to $2.5 million affecting workforce reduction (22 employees, representing approximately 32% of the Company’s workforce).
  - Type: restructuring
  - Charge: approximately $2.2 to $2.5 million
  - Affected area: workforce reduction
  - Headcount: 22 employees, representing approximately 32% of the Company’s workforce
  source text: a workforce reduction of 22 employees, representing approximately 32% of the Company’s workforce. The Company estimates that it will incur non-recurring charges of approximately $2.2 to $2.5 million in connection with the workforce reduction, primarily consisting of severance payments, employee benefits contributions and related costs. The Company expects that
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312524203889/0001193125-24-203889-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.